{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-23-000099","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.199833+00:00","generated_at":"2026-06-18T11:26:03.931524+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sesen Bio to pay $0.36/share special dividend and issue CVR upon merger close on March 7","bullets":["Special cash dividend of $75M (~$0.36/share) payable by March 10 to holders of record March 7, contingent on merger closing.","Each share receives one Contingent Value Right for potential proceeds from sale of Vicineum/preclinical assets and Roche milestone.","Merger with CARISMA Therapeutics approved by stockholders on March 2, expected to close March 7.","Dividend and CVR issuance contingent on closing of merger with CARISMA."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-23-000099","json":"https://secwatch.observer/filing/0001485003-23-000099.json","markdown":"https://secwatch.observer/filing/0001485003-23-000099.md","text":"https://secwatch.observer/filing/0001485003-23-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000099/0001485003-23-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000099/sesn-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:26:03.931524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}